Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > denosumab
denosumab
Wednesday 18 May 2016
trade names : Prolia and Xgeva
| WP |
Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone. It was developed by the biotechnology company Amgen.
Denosumab is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone and giant cell tumor of bone .
The most common side effects are joint and muscle pain in the arms or legs.
Denosumab is contraindicated in people with low blood calcium levels.
See also
